IL292359A - Prostate cancer treatment methods - Google Patents
Prostate cancer treatment methodsInfo
- Publication number
- IL292359A IL292359A IL292359A IL29235922A IL292359A IL 292359 A IL292359 A IL 292359A IL 292359 A IL292359 A IL 292359A IL 29235922 A IL29235922 A IL 29235922A IL 292359 A IL292359 A IL 292359A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- pct
- day
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924655P | 2019-10-22 | 2019-10-22 | |
| US201962945418P | 2019-12-09 | 2019-12-09 | |
| US202063028843P | 2020-05-22 | 2020-05-22 | |
| US202063032453P | 2020-05-29 | 2020-05-29 | |
| PCT/US2020/056684 WO2021081108A1 (en) | 2019-10-22 | 2020-10-21 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292359A true IL292359A (en) | 2022-06-01 |
Family
ID=73449188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292359A IL292359A (en) | 2019-10-22 | 2020-10-21 | Prostate cancer treatment methods |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210113557A1 (enExample) |
| EP (1) | EP4048236A1 (enExample) |
| JP (2) | JP7716396B2 (enExample) |
| KR (1) | KR20220087482A (enExample) |
| CN (1) | CN115135313A (enExample) |
| AU (1) | AU2020370150A1 (enExample) |
| CA (1) | CA3158411A1 (enExample) |
| IL (1) | IL292359A (enExample) |
| MX (1) | MX2022004808A (enExample) |
| WO (1) | WO2021081108A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| WO2022048605A1 (zh) * | 2020-09-04 | 2022-03-10 | 南昌奥瑞药业有限公司 | 一种杂环化合物、其制备方法、中间体、组合物以及应用 |
| WO2022087125A1 (en) * | 2020-10-21 | 2022-04-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor protein |
| US20220184078A1 (en) * | 2020-12-11 | 2022-06-16 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
| CN113620931B (zh) * | 2021-09-13 | 2023-06-09 | 中国海洋大学 | 一种雄激素受体抑制剂及其用途 |
| WO2023205481A1 (en) * | 2022-04-21 | 2023-10-26 | Arvinas Operations, Inc. | A combination for use in treating prostate cancer comprising arv-100 and abiraterone |
| WO2024233696A1 (en) * | 2023-05-09 | 2024-11-14 | Arvinas Operations, Inc. | Bavdegalutamide for treating prostate cancer without ar l702h mutation |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2015114314A1 (en) * | 2014-01-28 | 2015-08-06 | Cipla Limited | Pharmaceutical composition comprising abiraterone |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RS59490B1 (sr) * | 2014-11-21 | 2019-12-31 | Biohaven Therapeutics Ltd | Sublingvalna formulacija riluzola |
| AU2017278314B2 (en) * | 2016-06-10 | 2022-06-30 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| JOP20190067A1 (ar) * | 2016-09-30 | 2019-03-28 | Janssen Pharmaceutica Nv | طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
-
2020
- 2020-10-21 US US17/075,808 patent/US20210113557A1/en not_active Abandoned
- 2020-10-21 IL IL292359A patent/IL292359A/en unknown
- 2020-10-21 CN CN202080080511.2A patent/CN115135313A/zh active Pending
- 2020-10-21 WO PCT/US2020/056684 patent/WO2021081108A1/en not_active Ceased
- 2020-10-21 EP EP20807571.3A patent/EP4048236A1/en not_active Withdrawn
- 2020-10-21 AU AU2020370150A patent/AU2020370150A1/en not_active Abandoned
- 2020-10-21 JP JP2022523564A patent/JP7716396B2/ja active Active
- 2020-10-21 MX MX2022004808A patent/MX2022004808A/es unknown
- 2020-10-21 KR KR1020227016404A patent/KR20220087482A/ko not_active Ceased
- 2020-10-21 CA CA3158411A patent/CA3158411A1/en active Pending
-
2022
- 2022-12-21 US US18/085,869 patent/US20230128132A1/en not_active Abandoned
-
2025
- 2025-07-18 JP JP2025120941A patent/JP2025157436A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210113557A1 (en) | 2021-04-22 |
| AU2020370150A1 (en) | 2022-05-12 |
| WO2021081108A1 (en) | 2021-04-29 |
| JP2022553954A (ja) | 2022-12-27 |
| JP7716396B2 (ja) | 2025-07-31 |
| CA3158411A1 (en) | 2021-04-29 |
| KR20220087482A (ko) | 2022-06-24 |
| EP4048236A1 (en) | 2022-08-31 |
| US20230128132A1 (en) | 2023-04-27 |
| JP2025157436A (ja) | 2025-10-15 |
| MX2022004808A (es) | 2022-06-08 |
| CN115135313A (zh) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2978534T3 (es) | Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer | |
| ES2428291T3 (es) | Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos | |
| US20230128132A1 (en) | Methods of treating prostate cancer | |
| US5945412A (en) | Methods and compositions for preventing and treating bone loss | |
| JP6991993B2 (ja) | 痛覚過敏を治療する方法 | |
| US20250161280A1 (en) | Combination therapy using azabicyclo compound for cancer | |
| KR20230118147A (ko) | 전립선암 치료 방법 | |
| CA3214530A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
| RS66424B1 (sr) | Kombinovane terapije | |
| ES2736507T3 (es) | 2-Tioxo-imidazolidin-4-onas sustituidas y análogos espiro de las mismas, ingrediente activo contra el cáncer, composición farmacéutica, preparación medicinal, método para tratar cáncer de próstata | |
| US9358247B2 (en) | Methods and compositions for promoting activity of anti-cancer therapies | |
| US20120264795A1 (en) | Combination therapy with parp inhibitors | |
| TW202010502A (zh) | 包含糖皮質激素受體拮抗劑之固體形式與調配物及其用途 | |
| ES2762641T3 (es) | Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina | |
| SA520412533B1 (ar) | تثبيط قناة الأيون المحتملة للمستقبل العابر a1 | |
| US20020169166A1 (en) | Benzimidazoles that are useful in treating sexual dysfunction | |
| US20100286038A1 (en) | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same | |
| CN101485887B (zh) | 5-氟尿嘧啶-sn2-磷脂酰胆碱共聚物及其制备方法和用途 | |
| JP7420888B2 (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| PL211114B1 (pl) | Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej | |
| EP2575459A1 (en) | Cancer treatment with wortmannin analogs | |
| WO2022261643A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
| KR20100051837A (ko) | 소아 종양의 치료 | |
| EP3368056B1 (en) | Compositions and methods for sensitizing low responsive tumors to cancer therapy | |
| CN101601669B (zh) | 用于治疗肿瘤的联合用药物 |